Haemonetics Corporation (HAE)
Pretax margin
| Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 212,071 | 151,865 | 141,403 | 63,629 | 72,913 |
| Revenue | US$ in thousands | 1,360,820 | 1,309,060 | 1,168,660 | 993,196 | 870,463 |
| Pretax margin | 15.58% | 11.60% | 12.10% | 6.41% | 8.38% |
March 31, 2025 calculation
Pretax margin = EBT ÷ Revenue
= $212,071K ÷ $1,360,820K
= 15.58%
Haemonetics Corporation's pretax margin has exhibited fluctuations over the past five years, ranging from 6.41% to 15.58%. The margins for the periods ending on March 31, 2021, and March 31, 2022, stood at 8.38% and 6.41%, respectively, indicating a slight decrease in profitability. However, there was a significant improvement in the pretax margin for the subsequent years, with figures of 12.10% for March 31, 2023, and 11.60% for March 31, 2024, showing a positive trend in profitability.
The most recent data for the year ending March 31, 2025, reveals a notable increase in the pretax margin to 15.58%, indicating an improvement in the company's efficiency in generating profits before accounting for taxes. Overall, Haemonetics Corporation's pretax margin demonstrates variability, with recent years showing a positive trajectory and potentially reflecting effective cost management strategies and revenue growth.
Peer comparison
Mar 31, 2025